Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01247558 · ClinicalTrials.gov registry record

Administrative Claims Analysis of Metanx® in Diabetic Peripheral Neuropathy

A clinical trial of Diabetic Peripheral Neuropathy (DPN), sponsored by Pamlab, L.L.C..

Completed
Registry status
500
Enrollment target
1
Study location

NCT01247558: Completed study of Diabetic Peripheral Neuropathy (DPN), sponsored by Pamlab, L.L.C..

NCT01247558 is a study of Diabetic Peripheral Neuropathy (DPN) that has completed, run by Pamlab, L.L.C.. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01247558, a study of Diabetic Peripheral Neuropathy (DPN), has completed, sponsored by Pamlab, L.L.C..

COMPLETED
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

This study will be an observational cohort study utilizing administrative claims data with 100 patients randomly selected taking Metanx® meeting the inclusion and exclusion criteria and 400 propensity score matched patients meeting the same criteria to serve as a control cohort for analyses. This data includes medical, and pharmacy claims from the HealthCore Integrated Research Database for claims submitted during the time period of 01/01/2002 through 06/30/2007.

Primary Outcome

Total healthcare utilization and costs for patients treated with Metanx® will be compared to total healthcare utilization and costs for control patients who did not receive Metanx®. Cost data will be presented as Mean (SD) and median.

Interventions

  • OTHER Metanx® (a medical food)
  • OTHER Not treated with Metanx®

Study Locations (1)

Delaware

  • HealthCore, Inc. - Wilmington

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2010-11
Est. Completion 2011-09
Pamlab, L.L.C.

2 total trials

What the finished NCT01247558 record still lists

NCT01247558 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.

The record links to 1 condition, with Diabetic Peripheral Neuropathy (DPN) appearing as the primary indexed condition, and to 2 interventions - of which Metanx® (a medical food) is the first listed.

NCT01247558 reports a single indexed study location in Delaware.

Frequently Asked Questions

What is clinical trial NCT01247558 about?

NCT01247558 is a clinical study titled "Administrative Claims Analysis of Metanx® in Diabetic Peripheral Neuropathy". This study will be an observational cohort study utilizing administrative claims data with 100 patients randomly selected taking Metanx® meeting the inclusion and exclusion criteria and 400 propensity score matched patients meeting the same criteria to serve as a control cohort for analyses. This da...

What is the current status of trial NCT01247558?

This trial is currently completed. The enrollment target is 500 participants. The study started on 2010-11. Estimated completion is 2011-09.

What conditions does trial NCT01247558 study?

This clinical trial studies the following conditions: Diabetic Peripheral Neuropathy (DPN).

What interventions are being tested in trial NCT01247558?

The interventions under investigation include: Metanx® (a medical food) (OTHER), Not treated with Metanx® (OTHER).

Who is sponsoring clinical trial NCT01247558?

This trial is sponsored by Pamlab, L.L.C., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01247558 being conducted?

This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01247558, the US trial registry maintained by the National Library of Medicine. NCT01247558 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.